Recombinant Rabbit TFPI Protein，His & GST

Tissue factor pathway inhibitor (TFPI) is a critical regulator of the coagulation cascade, playing a vital role in maintaining hemostasis and preventing thrombosis. Discovered in the 1980s, TFPI acts primarily by inhibiting factor Xa and tissue factor (TF), thereby controlling the formation of the thrombin complex necessary for blood clotting. Given its central role in coagulation, researchers have focused on developing recombinant forms of TFPI for therapeutic applications. These recombinant proteins have potential use in treating various thromboembolic disorders, including deep vein thrombosis and pulmonary embolism, as well as in preventing clot formation in patients undergoing certain surgical procedures. The production of recombinant TFPI presents challenges, including ensuring proper folding, post-translational modifications, and bioactivity. Advances in biotechnology, such as genetic engineering techniques, have enabled the successful expression of TFPI in different host systems, including bacteria and mammalian cells. Recent studies have highlighted the efficacy of recombinant TFPI in preclinical models, demonstrating its ability to modulate coagulation pathways effectively. This progress paves the way for clinical trials aimed at evaluating its safety and efficacy, potentially offering new therapeutic avenues for patients at risk of thrombotic events. Overall, the research on TFPI recombinant proteins holds promise for enhancing our understanding of coagulation biology and developing targeted treatments for thrombotic diseases.